Over the past five years, Valeant Pharmaceuticals' (NYSE: VRX ) stock is up 856%, absolutely smashing the returns delivered by the market. And the company has recently made waves by teaming up with activist investor Bill Ackman of Pershing Square to take over Allergan (NYSE: AGN.DL ) , the specialty pharma company famous for Botox.
In the following video, Motley Fool analysts Michael Douglass and Brendan Mathews discuss the three things investors should be watching for at Valeant. Brendan notes that investors should keep a close eye on Valeant's organic growth, projected cash earnings per share, and achievement of synergies from past acquisitions, especially the Bausch + Lomb purchase. Check out the video below to learn more.
Will this stock be your next multibagger?
Give me five minutes and I'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks one stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year, his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252%, and 1,303% over the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.